Marc Abrams, PhDChief Technology Officer & Head, US Operations at SanegeneBioSpeaker
Profile
Marc has over 20 years' experience in discovery and development of genetic medicines, including RNAi and gene therapy. He started his career at Merck and Co. Inc., taking on roles of increasing responsibility in the early days of the field. More recently, Marc served as SVP, Discovery Research at Dicerna Pharmaceuticals (a Novo Nordisk Company) and as CSO of Carbon Biosciences. Marc is currently CTO & Head of US Operations at SanegeneBio, working on novel RNAi delivery strategies and target biology. His therapeutic area experience spans diverse indication spaces including oncology, antiviral and metabolic diseases. Marc has a Ph.D. in Biochemistry from Thomas Jefferson University.
Agenda Sessions
Novel Extrahepatic RNAi Therapeutics for Obesity Targeting Adipocytes and Skeletal Muscle via the LEAD™ Technology
, 8:30amView Session